Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology

References

• Lanna C, Mancini M, Gaziano R, et al., Skin immunity and its dysregulation in psoriasis. Cell Cycle. 2019. 18(20): 2581–2589.
   Google Scholar
• Armstrong AW, Pathophysiology RC, Presentation C. Treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960.
   Google Scholar
• Caputo V, Strafella C, Termine A, et al. Overview of the molecular determinants contributing to the expression of psoriasis and psoriatic arthritis phenotypes. J Cell Mol Med. 2020;24(23):13554–13563.
   Google Scholar
• Freitas E, Blauvelt A, Torres T. Bimekizumab for the treatment of psoriasis. Drugs. 2021;81(15):1751–1762.
   Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523–532.
   Google Scholar
• Amatya N, Garg AV, Gaffen SL. Gaffen SL. IL-17 signaling: the Yin and the Yang. Trends Immunol. 2017;38(5):310–322.
   Google Scholar
• Swaidani S, Liu C, Zhao J, et al. TRAF regulation of IL-17 cytokine signaling. Front Immunol. 2019;10:1293.
   Google Scholar
• Ruiz de Morales JMG, Puig L, Daudén E, et al. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: an updated review of the evidence focusing in controversies. Autoimmun Rev. 2020;19(1):102429.
   Google Scholar
• Lauffer F, Eyerich K, Boehncke W-H, et al. Cytokines of the IL-17 family in psoriasis. J Dtsch Dermatol Ges. 2020;18:675–681.
   Google Scholar
• Li X, Bechara R, Zhao J, et al. IL-17 receptor-based signaling and implications for disease. Nat Immunol. 2019;20(12):1594–1602.
   Google Scholar
• McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892–906.
   Google Scholar
• Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. Cytokine. 2013;64(2):477–485.
   Google Scholar
• Kagami S, Rizzo HL, Kurtz SE, et al. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol. 2010;185(9):5453–5462.
   Google Scholar
• Aggor FEY, Break TJ, Trevejo-Nuñez G, et al. Oral epithelial IL-22/STAT3 signaling licenses IL-17-mediated immunity to oral mucosal candidiasis. Sci Immunol. 2020;5(48):eaba0570.
   Google Scholar
• Conti HR, SL G. IL-17–Mediated immunity to the opportunistic fungal pathogen Candida albicans. J Immunol. 2015;195(3):780–788.
   Google Scholar
• Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27(1):485–517.
   Google Scholar
• Ma CS, Chew GYJ, Simpson N, et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205(7):1551–1557.
   Google Scholar
• Abusleme L, NM M. IL-17: overview and role in oral immunity and microbiome. Oral Dis. 2017;23(7):854–865.
   Google Scholar
• Valeri M, Cytokines RM, Napier B. IL-17 and IL-22 in the host response to infection. Pathog Dis. 2016;74(9):ftw111.
   Google Scholar
• Megna M, Napolitano M, Fabbrocini G. May IL-17 have a role in COVID-19 infection? Med Hypotheses. 2020;140:109749.
   Google Scholar
• Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395(10224):e35–e36.
   Google Scholar
• Iwakura Y, Ishigame H, Saijo S, et al. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149–162.
   Google Scholar
• Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35(4):824–834.
   Google Scholar
• Chen K, Kolls JK. Interluekin-17A (IL17A). Gene. 2017;614:8–14.
   Google Scholar
• Monteleone I, Sarra M, Pallone F, et al. Th17-related cytokines in inflammatory bowel diseases: friends or foes? Curr Mol Med. 2012;12(5):592–597.
   Google Scholar
• Ventura A, Mazzeo M, Gaziano R, et al. New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Des Devel Ther. 2017;11:2527–2535.
   Google Scholar
• Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16(3):185–196.
   Google Scholar
• Petitpain N, D’Amico F, Yelehe-Okouma M, et al. IL-17 inhibitors and inflammatory bowel diseases: a postmarketing study in vigibase. Clin Pharmacol Ther. 2021;110(1):159–168.
   Google Scholar
• Fauny M, Moulin D, D’Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132–1138.
   Google Scholar
• Fitzpatrick LR. Inhibition of IL-17 as a pharmacological approach for IBD. Int Rev Immunol. 2013;32(5–6):544–555.
   Google Scholar
• Waisman A, Hauptmann J, Regen T. The role of IL-17 in CNS diseases. Acta Neuropathol. 2015;129(5):625–637.
   Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;2012(61):1693–1700
   Google Scholar
• Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled Phase 2 study of brodalumab in patients with moderate-to-severe crohn’s disease. Am J Gastroenterol. 2016;111(11):1599–1607.
   Google Scholar
• Reich K, Leonardi C, Langley RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(441–448.e2):441–448.e2.
   Google Scholar
• Ait-Oufella H, Libby P, Tedgui A. Anticytokine immune therapy and atherothrombotic cardiovascular risk. Arterioscler Thromb Vasc Biol. 2019;39(8):1510–1519.
   Google Scholar
• Gisterå A, Robertson A-KL, Andersson J, et al. Transforming growth factor-β signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med. 2013;5(196ra100). 10.1126/scitranslmed.3006133.
   Google Scholar
• Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570–577.
   Google Scholar
• von Stebut E, Boehncke W-H, Ghoreschi K, et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096.
   Google Scholar
• Beurel E, Lowell JA. Th17 cells in depression. Brain Behav Immun. 2018;69:28–34.
   Google Scholar
• Tsuboi H, Sakakibara H, Minamida Y, et al. Elevated levels of serum IL-17A in community-dwelling women with higher depressive symptoms. Behav Sci (Basel). 2018;8(11):E102.
   Google Scholar
• Li Y-C, Chou Y-C, Chen H-C, et al. Interleukin-6 and interleukin-17 are related to depression in patients with rheumatoid arthritis. Int J Rheum Dis. 2019;22(6):980–985.
   Google Scholar
• Rusta-Sallehy S, Gooderham M, Brodalumab: PK. A review of safety. Skin Therapy Lett. 2018;23(2):1–3.
   Google Scholar
• Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther. 2019;19(4):287–292.
   Google Scholar
• Iznardo H, Puig L. The safety of brodalumab for the treatment of psoriasis. Expert Opin Drug Saf. 2020;19(4):365–372.
   Google Scholar
• Havrdová E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. J Neurol. 2016;263(7):1287–1295.
   Google Scholar
• Chang SH. T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer. Arch Pharm Res. 2019;42(7):549–559.
   Google Scholar
• Brevi A, Cogrossi LL, Grazia G, et al. Much more than IL-17A: cytokines of the IL-17 family between microbiota and cancer. Front Immunol. 2020;11:565470.
   Google Scholar
• Nicola S, Ridolfi I, Rolla G, et al. IL-17 promotes nitric oxide production in non-small-cell lung cancer. J Clin Med. 2021;10(19):4572.
   Google Scholar
• Li Q, Han Y, Fei G, et al. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett. 2012;148(2):144–150.
   Google Scholar
• Pan B, Che D, Cao J, et al. Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer. Biomarkers. 2015;20(4):232–239.
   Google Scholar
• Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: driving protection and pathology. Eur J Immunol. 2017;47(4):607–614.
   Google Scholar
• Nalbant A. IL-17, IL-21, and IL-22 cytokines of T helper 17 cells in cancer. J Interferon Cytokine Res. 2019;39(1):56–60.
   Google Scholar
• Campione E, Cosio T, Di Prete M, et al. Experimental pharmacological management of psoriasis. J Exp Pharmacol. 2021;13:725–737.
   Google Scholar
• Campione E, Cosio T, Lanna C, et al. Predictive role of vitamin A serum concentration in psoriatic patients treated with IL-17 inhibitors to prevent skin and systemic fungal infections. J Pharmacol Sci. 2020;144(1):52–56.
   Google Scholar
• Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390.
   Google Scholar
• Brembilla NC, Senra L, Boehncke W-H. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682.
   Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–1613.
   Google Scholar
• Sakkas LI, Zafiriou E, Bogdanos DP. Mini review: new treatments in psoriatic arthritis. focus on the IL-23/17 axis. Front Pharmacol. 2019;10:872.
   Google Scholar
• Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133–142.
   Google Scholar
• Boutet M-A, Nerviani A, Gallo Afflitto G, et al. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):E530.
   Google Scholar
• Craig S, Warren RB. Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opin Biol Ther. 2020;20(6):549–557.
   Google Scholar
• Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674–681.
   Google Scholar
• Warren RB, Barker JNWB, Finlay AY, et al. Secukinumab for patients failing previous tumour necrosis factor-α inhibitor therapy: results of a randomized open-label study (SIGNATURE). Br J Dermatol. 2020;183:60–70.
   Google Scholar
• Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023.
   Google Scholar
• AbuslemeElewski LB, NM M. guselkumab in patients with moderate-to-severe plaque psoriasisIL-17: 24-week efficacyoverview and safety results from a randomized, double-blinded trialrole in oral immunity and microbiome. Br J DermatolOral Dis. 20212017;18423(7):854–8651047–1058.
   Google Scholar
• Nash P, Kirkham B, Okada M, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317–2327.
   Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (Adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87.
   Google Scholar
• Malagoli P, Dapavo P, Pavia G, et al. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: a 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis), Dermatol Ther, 2022:e15608.
   Google Scholar
• Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352–359.
   Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(1183–1190.e3):1183–1190.e3.
   Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306.
   Google Scholar
• Kojanova M, Hugo J, Velackova B, et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022:1–11. DOI:10.1080/09546634.2022.2082354.
   Google Scholar
• Galluzzo M, Caldarola G, De Simone C, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21(9):1299–1310.
   Google Scholar
• Abrouk M, Gandy J, Nakamura M, et al. Secukinumab in the treatment of psoriasis and psoriatic Arthritis: a review of the literature. Skin Therapy Lett. 2017;22(4):1–6.
   Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(27–36.e1):27–36.e1.
   Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
   Google Scholar
• Lacour J-P, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31(5):847–856.
   Google Scholar
• Gottlieb AB, Blauvelt A, Prinz JC, et al. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial. J Drugs Dermatol. 2016;15(10):1226–1234.
   Google Scholar
• Thaçi D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777–787.
   Google Scholar
• Ohtsuki M, Morita A, Abe M, et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014;41(12):1039–1046.
   Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
   Google Scholar
• Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 study. ACR Open Rheumatol. 2020;2(1):18–25.
   Google Scholar
• Caldarola G, Mariani M, Pirro F, et al. Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opin Biol Ther. 2021;21(2):279–286.
   Google Scholar
• Natsis NE, Gottlieb AB. Bimekizumab for the treatment of psoriatic disease. Expert Opin Biol Ther. 2018;18(12):1193–1197.
   Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498.
   Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486.
   Google Scholar
• Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130–141.
   Google Scholar
• Gottlieb AB, Warren RB, Augustin M, et al. Psychometric validation of the psoriasis symptoms and impacts measure (p-sim): a novel patient-reported outcome instrument for patients with plaque psoriasis, using reported data from the BE RADIANT Phase 3b Trial. Adv Ther. 2021;38(10):5253–5269.
   Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362.
   Google Scholar
• Paller AS, Seyger MMB, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA - PEDS). Br J Dermatol. 2020;183(2):231–241.
   Google Scholar
• Ly K, Smith MP, Thibodeaux Q, et al. Anti IL-17 in psoriasis. Expert Rev Clin Immunol. 2019;15(11):1185–1194.
   Google Scholar
• Kearns DG, Uppal S, Chat VS, et al. Comparison of guidelines for the use of interleukin-17 inhibitors for psoriasis in the United States, Britain, and Europe: a critical appraisal and comprehensive review. J Clin Aesthet Dermatol. 2021;14(6):55–59.
   Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(81–89.e5):81–89.e5.
   Google Scholar
• Bellinato F, Gisondi P, Maurelli M, et al. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. Dermatol Ther. 2021;34(2):e14889.
   Google Scholar
• Saunte DM, Mrowietz U, Puig L, et al., Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017. 177(1): 47–62.
   Google Scholar
• Rodríguez-Cerdeira C, González-Cespón JL, Martínez-Herrera E, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Ital J Dermatol Venerol. 2021;156(5):545–557.
   Google Scholar
• Fritz Y, Klenotic PA, Swindell WR, et al. Induction of alternative proinflammatory cytokines accounts for sustained psoriasiform skin inflammation in IL-17C+IL-6KO Mice. J Invest Dermatol. 2017;137(3):696–705.
   Google Scholar
• Schön MP. Adaptive and innate immunity in psoriasis and other inflammatory disorders. Front Immunol. 2019;10:1764.
   Google Scholar
• Christophers E, Kerkhof PCM. van de Kerkhof PCM. Severity, heterogeneity and systemic inflammation in psoriasis. J Eur Acad Dermatol Venereol. 2019;33(4):643–647.
   Google Scholar
• Mehta H, Mashiko S, Angsana J, et al. Differential changes in inflammatory mononuclear phagocyte and t-cell profiles within psoriatic skin during treatment with guselkumab vs Secukinumab. J Invest Dermatol. 2021;141(1707–1718.e9).
   Google Scholar
• Vu TT, Koguchi-Yoshioka H, Skin-Resident Memory WR. T Cells: pathogenesis and Implication for the Treatment of Psoriasis. J Clin Med. 2021;10(17):3822.
   Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146.
   Google Scholar